Chronic myeloid leukemia (CML) is usually an insidious disease and the median age at diagnosis is stated in Hematology text books to be around 50 years. In the past, patients seek medical attention as a consequence of symptoms of vigorous hematopoiesis (fever, sweats, bone pain, weight loss, and fatigue) or signs of extramedullary hematopoiesis (splenomegaly and left upper quadrant discomfort). However, current medical practice and the periodic routine medical evaluation resulted in shifts in clinicohematologic picture and it is becoming more common for patients to be diagnosed before the development of symptoms . Considering such shift, it was expected that average age at diagnosis could be younger. However, the age was significantly lower in interferon studies than in recent imatinib mes…

Further information:

Article source

Related posts:

1. Novartis Drug Tasigna(R) Receives FDA Priority Review For Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
2. Novartis drug Tasigna® receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia
3. Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemia
4. FDA Approves Rituximab for Chronic Lymphocytic Leukemia
5. Mathematical Model Gives New Hope To Chronic Myeloid Leukaemia Patients